We suppose that people with T2DM and comorbidities, unlike those without, were additionally taking the organoprotective medications for blood pressure lowering (renin-angiotensin system blockers), statins and antiplatelet therapy. This evidence concerns the gene REN and type 2 diabetes mellitus.